Program
hyaluronidase (human recombinant)
Also written as “Efgartigimod PH20 SC”, “efgartigimod PH20 SC” and “rHuPH20”.
Its studies are mostly in Diabetes Mellitus, Type 1 · Myasthenia Gravis · Primary Immunodeficiency Diseases · Dehydration · Multiple Myeloma, led by 7 companies.
Drug pageHyaluronidase (human recombinant): every studyMany companies study it; this page follows only the 57 they lead. All 69 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| argenxits history only | 2211 open or running | phase 4since Oct 7, 2024 | Feb 20, 2020 | Mar 2027phase 2 · NCT06655155 |
| Halozyme Therapeutics | 200 open or running | phase 4since Apr 4, 2006 | Apr 4, 2006 | none ahead |
| Takedaits history only | 60 open or running | phase 3since Dec 23, 2008 | Oct 29, 2008 | none ahead |
| Hoffmann-La Rocheits history only | 42 open or running | phase 2since Sep 11, 2017 | Sep 11, 2017 | Aug 31, 2029phase 2 · NCT07503340 |
| Baxter Healthcareits history only | 30 open or running | phase 4since Dec 10, 2008 | Dec 10, 2008 | none ahead |
| Fosun Pharmaits history only | 11 open or running | phase 1since Feb 24, 2026 | Feb 24, 2026 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 1since Aug 6, 2015 | Aug 6, 2015 | none ahead |
Also a collaborator on its studies: BioLineRx.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Halozyme Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Apr 4, 2006.
- Apr 3, 2008Phase 4 study in HealthyNCT00656370 · 15 enrolled · United States
- Oct 15, 2008Phase 2 study in Diabetes Mellitus, Type 1NCT00774800 · 22 enrolled · United States
- Oct 15, 2008Phase 4 study in DehydrationNCT00773175 · 148 enrolled · United States
- Oct 29, 2008Phase 1 study in Non-Muscle Invasive Bladder NeoplasmsNCT00782587 · 14 enrolled · United States
- Dec 11, 2008Phase 1 study in Risk Factors for or a Diagnosis of OsteoporosisNCT00807963 · 31 enrolled · United States
- Mar 13, 2009Phase 1 study in Diabetes MellitusNCT00862849 · 22 enrolled · United States
- Apr 15, 2009Phase 2 study in Diabetes Mellitus, Type 1NCT00883558 · 48 enrolled · United States
- Jun 5, 20092 phase 2 studiesNCT00916357, NCT00928447
- Sep 17, 2009Phase 1 study in Insulin ResistanceNCT00979875 · 14 enrolled · United States
- Aug 31, 20102 phase 2 studiesNCT01194258, NCT01194245
- Jan 10, 2011Phase 1 study in Diabetes Mellitus, Type 1NCT01275131 · 45 enrolled · United States
- Jan 31, 2012Phase 4 study in Diabetes Mellitus, Type 1NCT01526733 · 25 enrolled · United States
- Apr 3, 2012Phase 1 study in HealthyNCT01572012 · 12 enrolled · United States
- Apr 29, 2013Phase 4 study in Diabetes Mellitus, Type 1NCT01848990 · 456 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 20 Halozyme Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01848990Diabetes Mellitus, Type 1 · United States | 4 | Completed | Feb 2014 | 456 |
| NCT01572012Healthy · United States | 1 | Completed | Nov 2013 | 12 |
| NCT01526733Diabetes Mellitus, Type 1 · United States | 4 | Completed | Aug 2012 | 25 |
| NCT01275131Diabetes Mellitus, Type 1 · United States | 1 | Completed | Dec 2011 | 45 |
| NCT01194258Diabetes Mellitus, Type 2 · United States | 2 | Completed | Aug 2011 | 132 |
| NCT01194245Diabetes Mellitus, Type 1 · United States | 2 | Completed | Aug 2011 | 135 |
| NCT00979875Insulin Resistance · United States | 1 | Completed | Feb 2010 | 14 |
| NCT00928447Dermatitis, Allergic Contact · United States | 2 | Completed | Sep 13, 2009 | 22 |
| NCT00916357Diabetes Mellitus, Type 2 · United States | 2 | Completed | Nov 2009 | 23 |
| NCT00883558Diabetes Mellitus, Type 1 · United States | 2 | Completed | Feb 2010 | 48 |
| NCT00862849Diabetes Mellitus · United States | 1 | Completed | Jun 2009 | 22 |
| NCT00807963Risk Factors for or a Diagnosis of Osteoporosis · United States | 1 | Completed | Sep 21, 2009 | 31 |
| NCT00782587Non-Muscle Invasive Bladder Neoplasms · United States | 1 | Completed | Mar 2009 | 14 |
| NCT00774800Diabetes Mellitus, Type 1 · United States | 2 | Completed | Mar 2009 | 22 |
| NCT00773175Dehydration · United States | 4 | Completed | Nov 2009 | 148 |
| NCT00656370Healthy · United States | 4 | Completed | Jan 30, 2008 | 15 |
| NCT00593281Pain · United States | 3 | Completed | Oct 2006 | 13 |
| NCT00435604Healthy | 1 | Completed | 15 | |
| NCT00318643Urinary Bladder Neoplasms · United States | 2 | Completed | Aug 11, 2009 | 27 |
| NCT00311519Healthy · United States | 4 | Completed | 50 |
How it is read
Names in the registry
- “Efgartigimod PH20 SC”, 12 entries
- “efgartigimod PH20 SC”, 10 entries
- “rHuPH20”, 5 entries
- “Recombinant human hyaluronidase PH20 (rHuPH20)”, 4 entries
- “recombinant human hyaluronidase”, 3 entries
Codes read as this program: RHUPH20.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 1, 6 studies
- Myasthenia Gravis, 5 studies
- Primary Immunodeficiency Diseases, 4 studies
- Dehydration, 4 studies
- Multiple Myeloma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.